https://www.selleckchem.com/ph....armacological_epigen
9%) patients underwent surgery, and 6/10 (60.0%) received postoperative adjuvant therapy. Only 23.1% of patients received nonsurgical therapy. The MDT discussed and managed seven patients before and/or after surgery and one patient who did not undergo surgery. The estimated 3- and 5-year overall survival (OS) rates were 50.0% and 30.0%, respectively. Patients who were managed by an MDT had a longer median OS time than those who were not (46.0 18.0 months). Age (P=0.018), tumor location (P=0.029), and Ki-67 (P=0.02 were foun
Like
Comment
Share
